Golde Named Physician-in Chief at Memorial Hospital

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 23 No 5
Volume 23
Issue 5

NEW YORK--Dr. David W. Golde has been appointed Physician-in-Chief of Memorial Hospital, Dr. Paul Marks, president of Memorial Sloan-Kettering Cancer Center, announced. Dr. Golde succeeds Joseph V. Simone, MD, who is to become clinical director for the Huntsman Cancer Institute, Salt Lake City.

NEW YORK--Dr. David W. Golde has been appointed Physician-in-Chiefof Memorial Hospital, Dr. Paul Marks, president of Memorial Sloan-KetteringCancer Center, announced. Dr. Golde succeeds Joseph V. Simone,MD, who is to become clinical director for the Huntsman CancerInstitute, Salt Lake City.

Dr. Golde was head of the Cancer Center's Division of HematologicOncology, Department of Medicine, as well as head of the Laboratoryof Molecular and Cellular Hematology at the Sloan-Kettering Institute.He is renowned for his contributions to the understanding of normaland leukemic blood cell growth. His demonstration that certainwhite blood cells produce colony-stimulating factors in humanslaid the groundwork for the isolation of these factors.

Recent Videos
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content